Vascular device developer Conor Medsystems reported that the Court of Appeal in the U.K. unanimously upheld the decision of the High Court of Justice to revoke the U.K. portion of European Patent 0 706 376 B1 to Angiotech Pharmaceuticals of Vancouver, British Columbia.
The Menlo Park, CA-based Conor said that the patent is exclusively licensed to Natick, MA-based Boston Scientific for use in the field of paclitaxel-eluting coronary stents.
Conor began the action to invalidate the patent in February 2005.
Angiotech said that the European Patent Office (EPO) has upheld the validity of its European counterpart of the U.K. patent, and that in all other designated member European countries of the EPO it continues to be enforceable.
By AuntMinnie.com staff writers
January 16, 2007
Related Reading
J&J's Conor acquisition gets FTC OK, January 9, 2007
Conor licenses Novartis technology, March 16, 2006
Conor Medsystems initiates CoStar II trial, May 24, 2005
Conor Medsystems nets CE Mark, May 10, 2005
Conor Medsystems inks distribution deal, May 27, 2004
Copyright © 2007 AuntMinnie.com
